Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Gene therapy treats muscular dystrophy in mice
US researchers have successfully used gene-editing  to treat mice with muscular dystrophy.
Technique has potential to be translated into human therapy

US researchers have successfully used a gene-editing technique to treat mice with Duchenne muscular dystrophy.

Researchers at Duke University used a system called CRISPR-Cas9 to remove DNA that was preventing cells from producing a protein essential for muscle function, while a virus was used to deliver DNA alterations into the cells of mice.

It is the first time the technique has succesfully treated a genetic disease inside a fully developed living mammal with a strategy that has the potential to be translated to human therapy.

Gershbach, associate professor of biomedical engineering at Duke University, explains: "Recent discussion about using CRISPR to correct genetic mutations in human embryos has rightfully generated considerable concern regarding the ethical implications of such an approach,”

“But using CRISPR to correct genetic mutations in the affected tissues of sick patients is not under debate. These studies show a path where that’s possible, but there’s still a considerable amount of work to do.”

Duchenne muscular dystrophy is caused by problems with the body's ability to produce dystrophin, a long protein chain that binds the interior of a muscle finer to its surrounding support structure.  

The condition affects one in 5,000 newborn males. Most patients are wheelchair-bound by the age of 10 and don't live beyond their early 30s.

The study, In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy, is published in Science. 

 

Become a member or log in to add this story to your CPD history

FIVP publishes CMA Compliance Checklist

News Story 1
 FIVP has published a CMA Compliance Checklist to support independent practices with the Market Investigation Order.

The document includes deadlines for small and large businesses, with tick boxes for each of the tasks. The organisation also invites practices to contact them for support with requirements.

Rita Dingwall, FIVP chair, said: FIVP appreciates that navigating the new CMA requirements can feel daunting. We hope this checklist will make things a little easier, helping independent practices work through what is required with confidence. 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.